Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Analgesic

or Anticonvulsant

or [[:Category:Methylxanthines|Methylxanthine (caffeine)]]

Use the filters below to narrow your results.

Brivaracetam (1) · Buprenorphine (1) · Butalbital / Acetaminophen / Caffeine (1) · Butalbital / Aspirin / Caffeine (1) · Butorphanol (1) · Cannabidiol (1) · Cenobamate (1) · Clobazam (1) · Codeine (2) · Dextropropoxyphene (1) · Dihydrocodeine (1) · Eslicarbazepine (1) · Ethosuximide (1) · Ethylmorphine (1) · Felbamate (1) · Fenfluramine (1) · Fentanyl (1) · Fosphenytoin (1) · Hydrocodone (1) · Hydromorphone (1) · Lacosamide (1) · Levorphanol (1) · Meperidine (1) · Methadone (1) · Nalbuphine (1) · Oxymorphone (1) · Papaverine (1) · Pentazocine (1) · Perampanel (1) · Phenobarbital (1) · Phenytoin (1) · Rufinamide (1) · Stiripentol (1) · Tapentadol (1) · Tiagabine (1) · Valproic acid (1) · Vigabatrin (1) · Zonisamide (1)

None (5) · (multiple, generic dominant) (1) · Aptiom (1) · Banzel (1) · Briviact (1) · Cerebyx (1) · Darvon (1) · Demerol (1) · Depakote (1) · Diacomit (1) · Dilantin (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · Epidiolex (1) · Felbatol (1) · Fintepla (1) · Fioricet, Esgic; with codeine as Fioricet with Codeine (Schedule III) (1) · Fiorinal; with codeine as Fiorinal with Codeine (Schedule III) (1) · Fycompa (1) · Gabitril (1) · Luminal (1) · Nubain (1) · Nucynta (1) · Onfi (1) · Opana (1) · Sabril (1) · Stadol (1) · Suboxone (1) · Talwin (1) · Vicodin (1) · Vimpat (1) · Xcopri (1) · Zarontin (1) · Zonegran (1)

None (2) · AMPA receptor antagonist (1) · GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) · GABA reuptake inhibitor (GAT-1 blocker) (1) · GABAA positive allosteric modulator (1) · GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) · GABAA potentiator and direct activator (1) · Irreversible GABA-T inhibitor (1) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; NMDA antagonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) · NMDA antagonist; GABAA potentiator (1) · Partial mu-opioid agonist; kappa antagonist (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Prodrug of phenytoin; sodium channel blocker (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Serotonin releaser; sigma-1 agonist (1) · Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) · Sodium channel blocker (2) · Sodium channel blocker; GABAA positive allosteric modulator (1) · Sodium channel modulator (1) · Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) · SV2A ligand (higher affinity than levetiracetam) (1) · T-type calcium channel blocker (1)

None (36) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-0000159D-QINU`"', '"`UNIQ--vote-0000159E-QINU`"' (1) · '"`UNIQ--vote-000015B6-QINU`"' (1)

None (36) · 1-2 capsules (50 mg butalbital / 325 mg acetaminophen / 40 mg caffeine each) PO every 4 hours as needed; maximum 6 capsules/d (1) · 1-2 capsules (50 mg butalbital / 325 mg aspirin / 40 mg caffeine each) PO every 4 hours as needed; maximum 6 capsules/d (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (36) · 50/325/40 mg capsules (1) · 50/325/40 mg capsules and tablets; oral solution (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (36) · 360 mg/day (1) · 6 capsules/d (300 mg butalbital, 1950 mg acetaminophen, 240 mg caffeine) (1) · 6 capsules/d (300 mg butalbital, 1950 mg aspirin, 240 mg caffeine) (1)

None (36) · Oral (2) · PO (only formulation marketed in the US). (1)

None (36) · 30-60 minutes (2) · 30–60 min (PO) (1)

None (36) · 4-6 hours (2) · 4–6 hours (1)

None (36) · 2.5–3 hours (1) · Butalbital ~35 hours (long; cumulative effects with frequent use); acetaminophen 1-3 hours; caffeine 3-7 hours'"`UNIQ--ref-0000159F-QINU`"' (1) · Butalbital ~35 hours; aspirin (acetyl group) ~15 minutes, salicylate 2-3 hours; caffeine 3-7 hours'"`UNIQ--ref-000015B7-QINU`"' (1)

None (36) · Butalbital well-absorbed; aspirin 50-75%; caffeine ~100%'"`UNIQ--ref-000015B8-QINU`"' (1) · Butalbital well-absorbed; caffeine ~100%; acetaminophen 85-98%'"`UNIQ--ref-000015A0-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (36) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Avoided; barbiturate + aspirin teratogenicity and bleeding concerns.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Generally avoided; barbiturate exposure in late pregnancy can produce neonatal withdrawal and respiratory depression.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (37) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Schedule III|Schedule III controlled substance]] in US (Fiorinal is scheduled federally; Fioricet with acetaminophen is unscheduled federally despite identical butalbital content, a regulatory quirk) (1)